Log in


-0.28 (-0.75 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $36.89
50-Day Range
MA: $38.43
52-Week Range
Now: $36.89
Volume3,800 shs
Average Volume7,501 shs
Market Capitalization$28.02 billion
P/E Ratio35.82
Dividend Yield0.49%
Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. It provides products for use in cardiothoracic surgery, interventional procedure, and medicine transfusion. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems. It also provides interventional oncology devices, such as micro balloon catheters, micro catheters and guide wires, and drug-elutable beads; cardiopulmonary bypass systems comprising oxygenators with integrated arterial filters, heart-lung machines, and devices for operating a centrifugal pumps for extracorporeal life support systems; and thoracic vascular and abdominal vascular grafts. In addition, the company offers infusion systems; closed anticancer drug infusion systems; blood glucose monitoring systems, digital blood pressure monitors, digital thermometers, pulse oximeters, walking intensity monitors, body composition monitors, and HR joint meter/monitors; sprayable adhesion barrier gels; analgesics; pharmaceuticals and nutritional supplements; and peritoneal dialysis devices and fluids. Further, it provides other consumer healthcare products, such as basal thermometers, fall prevention products, oral care products, and urine test strips; and blood bag systems with leukocyte reduction filters, automated blood collection and blood component processing systems, pathogen reduction technology systems, centrifugal apheresis systems, cell expansion systems, and autologous cell processing devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.94 out of 5 stars

Industry, Sector and Symbol

Industry Medical & hospital equipment
Previous SymbolNASDAQ:TRUMY



Sales & Book Value

Annual Sales$5.79 billion
Cash Flow$1.65 per share
Book Value$9.14 per share


Net Income$783.93 million


Market Cap$28.02 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive TRUMY News and Ratings via Email

Sign-up to receive the latest news and ratings for TRUMY and its competitors with MarketBeat's FREE daily newsletter.

TERUMO CORP/ADR (OTCMKTS:TRUMY) Frequently Asked Questions

How has TERUMO CORP/ADR's stock been impacted by COVID-19 (Coronavirus)?

TERUMO CORP/ADR's stock was trading at $32.71 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TRUMY stock has increased by 12.8% and is now trading at $36.89. View which stocks have been most impacted by Coronavirus.

When is TERUMO CORP/ADR's next earnings date?

TERUMO CORP/ADR is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for TERUMO CORP/ADR.

How were TERUMO CORP/ADR's earnings last quarter?

TERUMO CORP/ADR (OTCMKTS:TRUMY) posted its quarterly earnings data on Monday, May, 18th. The company reported $0.22 EPS for the quarter. The firm had revenue of $1.46 billion for the quarter. TERUMO CORP/ADR had a return on equity of 11.69% and a net margin of 13.55%. View TERUMO CORP/ADR's earnings history.

Has TERUMO CORP/ADR been receiving favorable news coverage?

Media coverage about TRUMY stock has trended neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TERUMO CORP/ADR earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about TERUMO CORP/ADR.

Who are some of TERUMO CORP/ADR's key competitors?

Who are TERUMO CORP/ADR's key executives?

TERUMO CORP/ADR's management team includes the following people:
  • Mr. David Brian Perez, Sr. Exec. Officer & Director (Age 60)
  • Mr. Shinjiro Sato, Pres, CEO & Director
  • Ryo Nishihata, Sr. Exec. Officer and Chief Accounting & Financial Officer
  • Mr. Hiroaki Kasukawa, CTO & Exec. Officer
  • Katsuya Takeuchi, Chief Information Officer & Exec. Officer

What is TERUMO CORP/ADR's stock symbol?

TERUMO CORP/ADR trades on the OTCMKTS under the ticker symbol "TRUMY."

How do I buy shares of TERUMO CORP/ADR?

Shares of TRUMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TERUMO CORP/ADR's stock price today?

One share of TRUMY stock can currently be purchased for approximately $36.89.

How big of a company is TERUMO CORP/ADR?

TERUMO CORP/ADR has a market capitalization of $28.02 billion and generates $5.79 billion in revenue each year. The company earns $783.93 million in net income (profit) each year or $1.04 on an earnings per share basis. TERUMO CORP/ADR employs 26,438 workers across the globe.

What is TERUMO CORP/ADR's official website?

The official website for TERUMO CORP/ADR is www.terumo.co.jp.

How can I contact TERUMO CORP/ADR?

TERUMO CORP/ADR's mailing address is 2-44-1 Hatagaya Shibuya-ku, Tokyo M0, 151-0072. The company can be reached via phone at 813-3374-8111 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.